NAMI works with policymakers to advance priority issues and ensure that the voice of people affected by mental illness is considered in policymaking. Read NAMI’s recent letters to federal leaders, submitted comments and testimony and other resources.
Letter to HHS Secretary on COVID-19
02/23/2021
Letter to HHS Acting Secretary Cochran, expressing thanks for the recent letter to Governors stating the public health emergency (PHE) declaration will likely remain in place throughout 2021.
Letter to Congressional Leadership on COVID-19 & Medicaid
02/23/2021
Letter to Congressional leadership, expressing support for the provision in the COVID relief reconciliation bill that will provide would provide additional funding for the direct care workforce within Medicaid Home and Community Based Services (HCBS).
Letter to Congressional Committee Leadership on COVID-19 & Telehealth
02/22/2021
Letter to Senate HELP & House Energy & Commerce Leadership, expressing support of the recent reintroduction of the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/S. 168), which would expand access to telehealth during the COVID public health emergency.
Letter to FDA Director on Medication Access
02/22/2021
Letter to FDA Center for Drug Evaluation and Research Director Choe, urging the FDA to commit to increased efficiency of generic reviews and greater attention to complex generics.
Comments to HHS Secretary on Medicaid
02/19/2021
Regulatory comments to HHS Acting Secretary Cochran, expressing support for Washington State’s request to extend a Medicaid demonstration program with an Institute for Mental Disease (IMD) waiver component.